Franziska Sotzny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7944182/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation, 2015, 125, 4196-4211.	3.9	258
2	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome – Evidence for an autoimmune disease. Autoimmunity Reviews, 2018, 17, 601-609.	2.5	199
3	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 2022, 20, 138.	1.8	116
4	Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Failure, 2020, 7, 1064-1071.	1.4	46
5	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine, 2021, 10, 3675.	1.0	38
6	HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. Frontiers in Immunology, 2020, 11, 607918.	2.2	37
7	TCF11/Nrf1-Mediated Induction of Proteasome Expression Prevents Cytotoxicity by Rotenone. Antioxidants and Redox Signaling, 2016, 25, 870-885.	2.5	33
8	Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset. Frontiers in Immunology, 2020, 11, 578.	2.2	29
9	Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. Frontiers in Immunology, 2021, 12, 687449.	2.2	26
10	Metformin Attenuates ROS via FOXO3 Activation in Immune Cells. Frontiers in Immunology, 2021, 12, 581799.	2.2	25
11	The expression signature of very long non-coding RNA in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 2018, 16, 231.	1.8	20
12	IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain, Behavior, & Immunity - Health, 2020, 3, 100047.	1.3	15
13	Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology. 2021. 12. 644548.	2.2	14
14	Serum Free Light Chains in CVID—a Marker for Differential Diagnosis. Journal of Clinical Immunology, 2018, 38, 163-165.	2.0	12
15	The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data. Heliyon, 2021, 7, e07665.	1.4	7
16	Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis. Frontiers in Medicine, 0, 9, .	1.2	7
17	Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study. Journal of Clinical Medicine, 2021, 10, 2420.	1.0	5